Photocure ASA (FRA:PHS)

Germany flag Germany · Delayed Price · Currency is EUR
5.21
-0.31 (-5.62%)
At close: Feb 20, 2026
Market Cap139.87M +5.4%
Revenue (ttm)45.00M +1.4%
Net Income-128.34K
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PE224.26
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume37
Open5.21
Previous Close5.52
Day's Range5.21 - 5.21
52-Week Range4.23 - 6.65
Betan/a
RSI38.45
Earnings DateFeb 18, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Industry Pharmaceutical Preparations
Founded 1993
Employees 101
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PHS
Full Company Profile

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.52% less than in 2024.

Financial numbers in NOK Financial Statements